Bionor Pharma ASA (BNRPF) 0.3800 $BNRPF
HIV-1 Infection - Pipeline Review, H1 2015
M2 - Wed May 13, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrjl97/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CompleGen, Inc. - Critical Outcome Technologies Inc. - CytoDyn Inc. - Enzo Biochem, Inc. - FIT Biotech Oy - GeneCure LLC - Gilead Sciences, Inc. - GlaxoSmithKline plc - Heat Biologics, Inc. - InnaVirVax SA - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Merck & Co., Inc. - Mymetics Corporation - Myrexis, Inc. - Oncovir, Inc. - OyaGen Inc. - Peregrine Pharmaceuticals, Inc. - Pfizer Inc. - Pharis Biotec GmbH - United Biomedical, Inc. - Valens Therapeutics, Inc. - Vichem Chemie Research Ltd. - ViiV Healthcare Limited For more information visit http://www.researchandmarkets.com/research/wr..._infection
HTBX: 5.75 (-0.02), PFE: 33.98 (-0.01), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), ARGS: 7.88 (+0.20), INO: 8.11 (+0.14), JNJ: 103.42 (+1.12), ENZ: 2.49 (-0.01), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22)
H1N1 Infection Pipeline Review 2015 - Analysis of 32 Companies & 55 Drug Profiles
M2 - Mon Apr 27, 11:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3glbfl/h1n1_infection) has announced the addition of the "H1N1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - Akshaya Bio Inc. - AlphaVax, Inc. - Antigen Express, Inc. - Beijing Minhai Biotechnology Co., Ltd - Bionor Pharma ASA - CEL-SCI Corporation - Cilian AG - Colby Pharmaceutical Company - Crucell N.V. - EpiVax, Inc. - Etubics Corporation - Gemmus Pharma Inc. - iBio, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Kyowa Hakko Kirin Co., Ltd. - Medicago Inc. - NanoViricides, Inc. - Onxeo SA - OPKO Health, Inc. - REPLICor Inc. - Revivicor, Inc. - Sarepta Therapeutics, Inc. - Sirnaomics, Inc. - TaiMed Biologics Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - Vaxart, Inc. - Vaxin, Inc. - Vaxine Pty Ltd For more information visit http://www.researchandmarkets.com/research/3g..._infection
JNJ: 103.42 (+1.12), INO: 8.11 (+0.14), CVM: 0.83 (-0.01), OPK: 17.30 (+0.38), SRPT: 15.93 (+0.72), IBIO: 0.92 (+0.03), NNVC: 1.66 (unch)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.01 (unch), AMRN: 1.91 (-0.02), HWAY: 16.94 (-0.29), HLS: 44.18 (+0.80), CYBX: 62.62 (+1.35), ESRX: 87.43 (+0.06), ECYT: 6.15 (+0.13), DXCM: 70.10 (+1.71), NSTG: 14.25 (-0.02), SRPT: 15.93 (+0.72), HZNP: 29.20 (+0.17), MDXG: 10.12 (+0.13), DEPO: 20.22 (-0.32), ANIK: 35.17 (+0.62), NKTR: 11.32 (+0.19), KERX: 10.50 (+0.17), ALIM: 4.48 (-0.01), EPZM: 18.82 (+1.39), AEGR: 19.47 (+0.19), MDRX: 14.08 (+0.10), ELGX: 16.42 (+0.29), NUVA: 47.42 (+0.69), HPTX: 45.99 (+0.02), GNMK: 9.57 (+0.17), MDVN: 125.90 (+3.00), HBIO: 5.34 (+0.10), ACAD: 40.31 (+1.14), ST: 55.21 (-0.29), RPTP: 11.55 (+0.24), FMI: 35.49 (-1.60), GMED: 25.79 (+0.67), JAZZ: 180.06 (+2.05), PTCT: 51.99 (-0.10), INFI: 12.92 (+0.62), ARNA: 4.39 (+0.14), EXEL: 3.34 (-0.03), NEO: 4.99 (+0.03), EXAS: 24.30 (+1.33), ALKS: 60.47 (+0.47), HTWR: 75.36 (+0.15), MNKD: 4.40 (+0.41), IPXL: 45.20 (+0.76), SQNM: 3.74 (+0.05), HALO: 17.03 (+0.61), ISIS: 64.33 (+1.78), CLVS: 93.36 (+0.62), BIO: 147.30 (+1.14), BIOS: 4.02 (-0.02), PCRX: 78.72 (+0.89)
David Horn Solomon assumes the role as President and Chief Executive Officer of Bionor Pharma ASA
GlobeNewswire - Fri Jan 09, 10:51AM CST
Bionor Pharma ASA (OSE:BIONOR) announces the appointment of Dr David Horn Solomon as new President and Chief Executive Officer. Dr Solomon will join the Company from NASDAQ OMX listed healthcare company Zealand Pharma A/S (NASDAQ:ZEAL), where he has served as President and CEO since September 2008.
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
Marketwired - Wed Nov 19, 3:29PM CST
Bionor Pharma ASA (OSLO: BIONOR)
CELG: 116.37 (+0.84)
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
Marketwired - Wed Nov 19, 2:35PM CST
Bionor Pharma ASA (OSLO: BIONOR)
CELG: 116.37 (+0.84)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 13.07 (+0.41), INO: 8.11 (+0.14), ADXS: 20.90 (+0.82), GSK: 44.66 (-0.11), NKTR: 11.32 (+0.19), NVS: 104.06 (+0.31)
HIV-1 Infection - Pipeline Review, H1 2015
M2 - Wed May 13, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wrjl97/hiv1_infection) has announced the addition of the "HIV-1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaVax, Inc. - AltraVax Inc. - Aphios Corporation - Argos Therapeutics, Inc. - Bionor Pharma ASA - Biosantech SA - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CompleGen, Inc. - Critical Outcome Technologies Inc. - CytoDyn Inc. - Enzo Biochem, Inc. - FIT Biotech Oy - GeneCure LLC - Gilead Sciences, Inc. - GlaxoSmithKline plc - Heat Biologics, Inc. - InnaVirVax SA - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Merck & Co., Inc. - Mymetics Corporation - Myrexis, Inc. - Oncovir, Inc. - OyaGen Inc. - Peregrine Pharmaceuticals, Inc. - Pfizer Inc. - Pharis Biotec GmbH - United Biomedical, Inc. - Valens Therapeutics, Inc. - Vichem Chemie Research Ltd. - ViiV Healthcare Limited For more information visit http://www.researchandmarkets.com/research/wr..._infection
HTBX: 5.75 (-0.02), PFE: 33.98 (-0.01), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), ARGS: 7.88 (+0.20), INO: 8.11 (+0.14), JNJ: 103.42 (+1.12), ENZ: 2.49 (-0.01), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22)
H1N1 Infection Pipeline Review 2015 - Analysis of 32 Companies & 55 Drug Profiles
M2 - Mon Apr 27, 11:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3glbfl/h1n1_infection) has announced the addition of the "H1N1 Infection - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H1N1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H1N1 Infection and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adamas Pharmaceuticals, Inc. - Akshaya Bio Inc. - AlphaVax, Inc. - Antigen Express, Inc. - Beijing Minhai Biotechnology Co., Ltd - Bionor Pharma ASA - CEL-SCI Corporation - Cilian AG - Colby Pharmaceutical Company - Crucell N.V. - EpiVax, Inc. - Etubics Corporation - Gemmus Pharma Inc. - iBio, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Kyowa Hakko Kirin Co., Ltd. - Medicago Inc. - NanoViricides, Inc. - Onxeo SA - OPKO Health, Inc. - REPLICor Inc. - Revivicor, Inc. - Sarepta Therapeutics, Inc. - Sirnaomics, Inc. - TaiMed Biologics Inc. - Takeda Pharmaceutical Company Limited - TechnoVax, Inc. - Vaxart, Inc. - Vaxin, Inc. - Vaxine Pty Ltd For more information visit http://www.researchandmarkets.com/research/3g..._infection
JNJ: 103.42 (+1.12), INO: 8.11 (+0.14), CVM: 0.83 (-0.01), OPK: 17.30 (+0.38), SRPT: 15.93 (+0.72), IBIO: 0.92 (+0.03), NNVC: 1.66 (unch)
Next Week In Biotech: Arena And Vivus Report, Radiesse And Avedro Ad Comms
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
LXRX: 1.01 (unch), AMRN: 1.91 (-0.02), HWAY: 16.94 (-0.29), HLS: 44.18 (+0.80), CYBX: 62.62 (+1.35), ESRX: 87.43 (+0.06), ECYT: 6.15 (+0.13), DXCM: 70.10 (+1.71), NSTG: 14.25 (-0.02), SRPT: 15.93 (+0.72), HZNP: 29.20 (+0.17), MDXG: 10.12 (+0.13), DEPO: 20.22 (-0.32), ANIK: 35.17 (+0.62), NKTR: 11.32 (+0.19), KERX: 10.50 (+0.17), ALIM: 4.48 (-0.01), EPZM: 18.82 (+1.39), AEGR: 19.47 (+0.19), MDRX: 14.08 (+0.10), ELGX: 16.42 (+0.29), NUVA: 47.42 (+0.69), HPTX: 45.99 (+0.02), GNMK: 9.57 (+0.17), MDVN: 125.90 (+3.00), HBIO: 5.34 (+0.10), ACAD: 40.31 (+1.14), ST: 55.21 (-0.29), RPTP: 11.55 (+0.24), FMI: 35.49 (-1.60), GMED: 25.79 (+0.67), JAZZ: 180.06 (+2.05), PTCT: 51.99 (-0.10), INFI: 12.92 (+0.62), ARNA: 4.39 (+0.14), EXEL: 3.34 (-0.03), NEO: 4.99 (+0.03), EXAS: 24.30 (+1.33), ALKS: 60.47 (+0.47), HTWR: 75.36 (+0.15), MNKD: 4.40 (+0.41), IPXL: 45.20 (+0.76), SQNM: 3.74 (+0.05), HALO: 17.03 (+0.61), ISIS: 64.33 (+1.78), CLVS: 93.36 (+0.62), BIO: 147.30 (+1.14), BIOS: 4.02 (-0.02), PCRX: 78.72 (+0.89)
David Horn Solomon assumes the role as President and Chief Executive Officer of Bionor Pharma ASA
GlobeNewswire - Fri Jan 09, 10:51AM CST
Bionor Pharma ASA (OSE:BIONOR) announces the appointment of Dr David Horn Solomon as new President and Chief Executive Officer. Dr Solomon will join the Company from NASDAQ OMX listed healthcare company Zealand Pharma A/S (NASDAQ:ZEAL), where he has served as President and CEO since September 2008.
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV
Marketwired - Wed Nov 19, 3:29PM CST
Bionor Pharma ASA (OSLO: BIONOR)
CELG: 116.37 (+0.84)
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV
Marketwired - Wed Nov 19, 2:35PM CST
Bionor Pharma ASA (OSLO: BIONOR)
CELG: 116.37 (+0.84)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 13.07 (+0.41), INO: 8.11 (+0.14), ADXS: 20.90 (+0.82), GSK: 44.66 (-0.11), NKTR: 11.32 (+0.19), NVS: 104.06 (+0.31)
